Liver-Related Death in HIV/HCV Coinfected Individuals: Who Should Be Targeted for HCV Treatment?
Background: The arrival of potent and less toxic directly acting agents (DAA) for treatment of HCV infection may see improved outcomes and less toxicity among HIV coinfected patients. The costs of treatment may necessitate prioritisation of those at greatest risk of liver-related death (LRD) for therapy. Further understanding of LRD among HIV/HCV coinfected individuals is…